Pharmacokinetics (PK) of gemcitabine (Gem), capecitabine (Cap), and erlotinib (Erlo) given in combination in patients with pancreatic carcinoma.

Marie-Christine Etienne-Grimaldi,Eric Francois,Nicole Renée,J. Bennouna,Christine Bobin-Dubigeon,Philippe Follana,Veronique Mari,E. Chamorey,Ludovic Evesque,G. A. Milano

Pharmacokinetics (PK) of gemcitabine (Gem), capecitabine (Cap), and erlotinib (Erlo) given in combination in patients with pancreatic carcinoma.

2010

Marie-Christine Etienne-Grimaldi
Eric Francois
Nicole Renée
J. Bennouna
Christine Bobin-Dubigeon
Philippe Follana
Veronique Mari
E. Chamorey
Ludovic Evesque
G. A. Milano

e13116 Background: The aim was to describe the PK of Erlo, Cap, and Gem, given in combination in the phase I CAPERGEM trial, performed in advanced pancreatic cancer patients. Methods: This study wa...

Keywords:

Pathology
Carcinoma
Capecitabine
Gemcitabine
Erlotinib
Internal medicine
Oncology
Cancer research
Medicine
Pharmacokinetics
Pancreatic cancer
pancreatic carcinoma
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations